Korea S.E.
06:00:00 2024-04-25 pm EDT
5-day change
1st Jan Change
20,050
KRW
+0.80%
+3.62%
-4.52%
Macrogen, Inc. authorizes a Buyback Plan.
The Board of Directors of Macrogen, Inc. has authorized a buyback plan on November 2, 2020.
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.
23-10-24
CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.
23-10-24
CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.
23-10-24
CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.
23-10-24
CI
Macrogen, Inc.'s Equity Buyback announced on October 21, 2022, has expired with 138,097 shares, representing 1.37% for KRW 2,825.59 million.
23-10-19
CI
Macrogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-23
CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022.
23-01-25
CI
Macrogen, Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.
22-10-21
CI
Macrogen, Inc. authorizes a Buyback Plan.
22-10-20
CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020.
21-10-31
CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020.
21-10-31
CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020.
21-10-31
CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020.
21-10-31
CI
Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on November 2, 2020.
21-10-31
CI
Macrogen, Inc.'s Equity Buyback announced on November 2, 2020, has expired with 168,300 shares, representing 1.72% for KRW 4,957.38 million.
21-10-31
CI
Macrogen, Inc.(KOSDAQ:A038290) added to S&P Global BMI Index
21-09-20
CI
Macrogen, Inc.(KOSDAQ:A038290) dropped from S&P Global BMI Index
21-03-22
CI
Macrogen, Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares.
20-11-01
CI
Macrogen, Inc. authorizes a Buyback Plan.
20-11-01
CI
Macrogen Signs Export Agreement with LG International
20-09-23
CI
Macrogen, Inc. Obtains Export Approval for COVID-19 Test Kit AxenTM Covid-19 RT
20-05-20
CI
Macrogen Approves for Export of Its COVID-19 Test Kit
20-05-20
CI
Macrogen Signs License and Supply Agreement with Thermo Fisher Scientific
20-01-13
CI
Macrogen, Inc.’s Equity Buyback announced on January 11, 2019, has expired.
20-01-09
CI
Seoul National University Bundang Hospital and Macrogen Announce Construction of Northeast Asian Reference Panel
19-12-02
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Macrogen, Inc. is a Korea-based company mainly engaged in the customized transgenic and other services in the field of biomedical research. The Company operates its business through four divisions: deoxyribonucleic acid (DNA) sequencing division, DNA chips division, transgenic and knockout mouse division and oligonucleotide DNA division. Its DNA sequencing division provides genome sequencing analysis services. Its DNA chips division develops DNA chips products, such as Illumina chips, MacArray chips and customized chips. Its transgenic and knockout mouse division offers gene engineering services. Its oligonucleotide DNA division offers oligonucleotide DNA manufacturing services. The Company operates its business within domestic market and in overseas markets.
More about the company
Last Close Price
20,050
KRW
Average target price
30,000
KRW
Spread / Average Target
+49.63%
Consensus
1st Jan change
Capi.
-4.52% 145M +2.28% 42.75B +47.81% 41.61B +11.85% 41.34B -12.36% 26.59B +8.25% 25.49B -24.16% 18.12B +29.79% 12.24B -2.26% 11.76B +7.59% 11B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
MACROGEN, INC. 
